Your browser doesn't support javascript.
loading
The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival
Oven Ustaalioglu, BB; Balvan, O; Bilici, A; Develi, A; Aliustaoglu, M; Vardar, FA; Erkol, B.
Afiliação
  • Oven Ustaalioglu, BB; Haydarpasa Numune Education and Research Hospital. Department of Medical Oncology. Istanbul. Turkey
  • Balvan, O; Dr. Lutfi Kirdar Kartal Education and Research Hospital. Department of Medical Oncology. Istanbul. Turkey
  • Bilici, A; Medipol University. Department of Medical Oncology. Istanbul. Turkey
  • Develi, A; Dr. Lutfi Kirdar Kartal Education and Research Hospital. Department of Medical Oncology. Istanbul. Turkey
  • Aliustaoglu, M; Dr. Lutfi Kirdar Kartal Education and Research Hospital. Department of Medical Oncology. Istanbul. Turkey
  • Vardar, FA; Haydarpasa Numune Education and Research Hospital. Department of Pathology. Istanbul. Turkey
  • Erkol, B; Haydarpasa Numune Education and Research Hospital. Department of Medical Oncology. Istanbul. Turkey
Clin. transl. oncol. (Print) ; 17(11): 895-902, nov. 2015. tab
Artigo em Inglês | IBECS | ID: ibc-143461
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT
Purpose. In the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancer patients and also prognostic factors related with recurrence-free survival (RFS) in recurrent patients. Patients/methods. We evaluated retrospectively 1980 breast cancer patients. Relapsed was defined as early if it was occured first 5 year of follow-up (Group 1) and late if it was occured after 5 years (Group 2). The clinicopathological factors were compared in respect of time of recurrence. The prognostic factors were evaluated using univariate and multivariate analyses. Results. Recurrence wase detected in 141 patient during follow-up. Tumors recurred after 5 years more likely to have lower stage (p = 0.05), tumors without lymphovascular invasion (LVI) (p < 0.001) and perineural invasion (PNI) (p = 0.01), and also HER2 negative (p < 0.001). The median RFS time and 5 years RFS rates were 42.9 months and 31.9 %, respectively. LVI (p = 0.01), PNI (p = 0.03), HER2 (p = 0.003), progesterone receptor (PR) (p = 0.04), the presence of neoadjuvant chemotherapy (p = 0.003), adjuvant hormonotherapy (p = 0.05) were found to be related with RFS. Axillary lymph node metastasis (p = 0.05) and the presence of PNI (p = 0.009) were poor prognostic factors for early recurrent group. PR-positive tumors (p = 0.001) and luminal subtypes (p = 0.03) had instances of late recurrences significantly. Conclusions. Clinicopathological factors predicting the recurrence time in breast cancer were important to modify adjuvant therapy (AU)
RESUMEN
No disponible
Assuntos
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Progesterona / Neoplasias da Mama / Terapia Neoadjuvante / Mastectomia / Recidiva Local de Neoplasia Tipo de estudo: Estudo de avaliação / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2015 Tipo de documento: Artigo Instituição/País de afiliação: Dr. Lutfi Kirdar Kartal Education and Research Hospital/Turkey / Haydarpasa Numune Education and Research Hospital/Turkey / Medipol University/Turkey
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Progesterona / Neoplasias da Mama / Terapia Neoadjuvante / Mastectomia / Recidiva Local de Neoplasia Tipo de estudo: Estudo de avaliação / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2015 Tipo de documento: Artigo Instituição/País de afiliação: Dr. Lutfi Kirdar Kartal Education and Research Hospital/Turkey / Haydarpasa Numune Education and Research Hospital/Turkey / Medipol University/Turkey
...